Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
J Herrmann, D Lenihan, S Armenian… - European heart …, 2022 - academic.oup.com
Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …
Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor–associated myocarditis: a narrative review
LH Lehmann, J Cautela, N Palaskas, AH Baik… - JAMA …, 2021 - jamanetwork.com
Importance In the last decade, immune checkpoint inhibitors (ICIs) have been approved for
the treatment of many cancer types. Immune checkpoint inhibitor–associated myocarditis …
the treatment of many cancer types. Immune checkpoint inhibitor–associated myocarditis …
Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque
Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers.
Consistent basic data suggest that these same checkpoints are critical negative regulators of …
Consistent basic data suggest that these same checkpoints are critical negative regulators of …
Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis
JE Salem, M Bretagne, B Abbar, S Leonard-Louis… - Cancer Discovery, 2023 - AACR
Abstract Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart
(myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are …
(myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are …
Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio‐oncology guidelines
J Alexandre, J Cautela, S Ederhy… - Journal of the …, 2020 - Am Heart Assoc
The considerable progress made in the field of cancer treatment has led to a dramatic
improvement in the prognosis of patients with cancer. However, toxicities resulting from …
improvement in the prognosis of patients with cancer. However, toxicities resulting from …
Heart failure association of the ESC, heart failure society of America and Japanese heart failure society position statement on endomyocardial biopsy
PM Seferović, H Tsutsui, DM McNamara… - European Journal of …, 2021 - Wiley Online Library
Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the
monitoring of heart transplant (HTx) rejection. In addition, EMB can have an important …
monitoring of heart transplant (HTx) rejection. In addition, EMB can have an important …
[HTML][HTML] Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Expanding the US Food and Drug Administration–approved indications for immune
checkpoint inhibitors in patients with cancer has resulted in therapeutic success and …
checkpoint inhibitors in patients with cancer has resulted in therapeutic success and …
Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor–associated myocarditis
P Thavendiranathan, L Zhang, A Zafar… - Journal of the American …, 2021 - jacc.org
Background Myocarditis is a potentially fatal complication of immune checkpoint inhibitor
(ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 …
(ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 …
The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer
L Zhang, KL Reynolds, AR Lyon, N Palaskas… - Cardio Oncology, 2021 - jacc.org
Immune checkpoint inhibitors (ICIs) are newer therapies being applied to an increasing
number of patients with cancer. Data suggest that up to 36% of cancer patients may be …
number of patients with cancer. Data suggest that up to 36% of cancer patients may be …
Cardiovascular complications of immune checkpoint inhibitors for cancer
Over the last decade or so, there has been a paradigm shift in the oncologic care of patients
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …